David g. Morgan, ph. D. 1 Jan 2009

Скачать 154.23 Kb.
НазваниеDavid g. Morgan, ph. D. 1 Jan 2009
Размер154.23 Kb.
1   2   3   4

Morgan, D., L. Holcomb, I. Saad, M. Gordon and M. Maines (1998). Impaired spatial navigation learning in transgenic mice over-expressing heme oxygenase-1. Brain Research, 808:110-112.

62) Gordon, M.N. C.D Mueller, K.A. Sherman, D.G. Morgan, A. Azarro, G. Bobotas and L. Wecker (1999). Oral versus transdermal selegiline: Antidepressant-like activity in rats. Pharmacology, Biochemistry and Behavior, 63:501-506

63) Pennypacker, K. R., Hernandez, H, Benkovic, S., Morgan, D. G., Willing, A. E. and Sanberg, P. R. (1999). Induction of presenilins in the rat brain after middle cerebral arterial occlusion. Brain Research Bulletin 48:539-543.

64) Holcomb, L.A., M.N. Gordon, P. Jantzen, K. Hsiao, K. Duff and D. Morgan (1999). Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits Behavior Genetics, 29:177-185

65) K.A. Wright, D.G. Morgan, X. Yu, J.R. Goss, J.M. Salbaum, K. Duff and M.N. Gordon (1999). Mice transgenic for a human amyloid precursor protein promoter-lacZ reporter construct: Appropriate cell type expression but not regulation in brain. J. Molecular Neurosci., 13:111-120.

66). Holcomb, L.A., M.N. Gordon, S.A. Benkovic and D.G. Morgan (2000). Aß and perlecan in rat brain. Glial activation, gradual clearance and limited neurotoxicity. Mechanisms Ageing and Development, 112:135-152.

67). Morgan,D, (2000). The intersection of Alzheimer's disease and typical aging. Neurobiology of Aging 21:159-161

68). Jaffar, S. , S.E. Counts, S.Y. Ma, E. Dadko, M.N. Gordon, D. Morgan and E.J. Mufson. (2000). Neuropathologic alterations in mutant APPswe and PS1m146l and doubly transgenic mice: a selective increase in p75ntr-containing basal forebrain neurons. Experimental Neurology, 170:227-243.

69). Morgan, D., D.M. Diamond, P. Gottschall, K.E. Ugen, C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, D. Wilcock, K. Connor, J. Hatcher, M. Gordon and G.W. Arendash (2000). Vaccination with Aß Peptide Prevents Memory Deficits in an Animal Model of Alzheimer=s Disease. Nature 408:982-985.

70). Gordon, M. N., King, D. L., Diamond, D. M., Jantzen, P. T., Boyett, K. L., Hope, C. E., Hatcher, J. M., DiCarlo, G., Gottschall, P., Morgan, D. & Arendash, G. W. (2001). Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice. Neurobiology of Aging 22:377-385

71). Nilsson, L.N.G., K.R.Bales, G. DiCarlo, M.N. Gordon, D. Morgan , S.M. Paul & H. Potter (2001). Alpha-1-antichymotrypsin promotes ß-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer=s disease. Journal of Neuroscience 21: 1444-1451

72). Arendash, G. W., King, D. L., Gordon, M. N., Morgan, D., Hatcher, J. M., Hope, C. E. & Diamond, D. M. (2001) Progressive behavioral impairments in transgenic mice carrying both mutant APP and PS1 transgenes. Brain Research 891:45-53

73). Arendash, G.W., M.N. Gordon, D.M. Diamond, J.M. Hatcher, L.A. Austin, P. Jantzen, D. DiCarlo, D. Wilcock and D. Morgan (2001). Behavioral benefits of Aß vaccination in Alzheimer=s transgenic mice. DNA and Cell Biology 20:737-744.

74). Dickey, C.A., D.G. Morgan, M.N. Gordon and K.E. Ugen (2001). Duration and specificity of the humoral responses im mice vaccinated with the Alzheimer's disease associated amyloid ß 1-42 peptide. DNA and Cell Biology 20:723-730.

75). DiCarlo, G., D. Wilcock, D. Henderson, M. Gordon, and D. Morgan (2001). Intrahippocampal LPS injections reduce Aß load in APP+PS1 transgenic mice. Neurobiology of Aging 22: 1007-1012.

76). Wilcock,D.M., M.N. Gordon, K.E Ugen, P.E. Gottschall, G. DiCarlo, C. Dickey, K.W. Boyett, P.T. Jantzen, K.E. Connor, J. Melachrino, J. Hardy and D. Morgan (2001). Number of Aß inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation and congophilic plaque levels. DNA and Cell Biology 20:731-736

77). Gordon, M.N., and D.G. Morgan (2001). Transgenic mice, inflammation and the Alzheimer phenotype. In Inflammatory Events in Neurodegeneration, S.C Bondy and A. Campbell (eds), Prominent Press, pp 98-118.

78). Gordon, M.N., L.A. Holcomb, P. Jantzen, G. DiCarlo, D. Wilcock, K. Connor, J. Melachrino, J. O'Callaghan and D. Morgan (2002). Time course of the development of Alzheimer-like pathology in the doubly transgenic mPS1+mAPP mouse. Experimental Neurology 173:183-195

79). Morgan,D., and R.K. Keller (2002) What evidence would prove the amyloid hypothesis? Towards rational drug treatments for Alzheimer's disease. Journal of Alzheimer's Disease 3:257-260

80). Jantzen, P.T.,K.E. Connor, G. DiCarlo, G.L. Wenk, J.L. Wallace, A.M. Rojiani, D. Coppola, D. Morgan, and Marcia N. Gordon (2002). Microglial Activation and Aß Deposit Reduction Caused by a Nitric Oxide Releasing NSAID, NCX-2216, in APP+PS1 Transgenic Mice. Journal of Neuroscience 22:2246-2254.

81) Ugen, K.E., C. Cao, C. Dickey, D. Wilcock, Y. Bai, M.N. Gordon and D. Morgan (2003). Characterization of amyloid beta vaccination strategies in mice.In Immunization against Alzheimer's Disease and Other Neurodegenerative Disorders. Springer-Verlag, Berlin, pp21-32

82) Morgan, D and M.N. Gordon (2003). The amyloid hypothesis of cognitive decline. In Neuroinflammation: Mechanisms and Management 2nd Edn. , P. Wood (ed.), Humana Press, pp283-294.

83) Morgan, D. (2003) Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochemical Research:28:1029-1034.

84) Morgan, D., P. Jantzen, D. Wilcock, G. DiCarlo, K. Ugen and M. Gordon (2003) The association of microglial activation and amyloid reduction in APP+PS1 transgenic mice. Current Medicinal Chemistry- Immunologic, Endocrinologic and Metabolic Agents 3:233-243

85) Austin,L.A., G.W. Arendash, M.N. Gordon, D.M. Diamond, G. DiCarlo, C. Dickey, K. Ugen, D. Morgan (2003) Short-term Aß vaccines do not improve cognitive performance in cognitively impaired APP+PS1 mice. Behavioral Neuroscience 117:478-484

86) Morgan, D (2003) Antibody therapy for Alzheimer's disease. Expert Review of Vaccines 2: 89-95.

87) Wilcock,D., G. DiCarlo, D. Henderson, J. Jackson, K. Clarke, K.E. Ugen, M.N. Gordon and D. Morgan (2003). Intracranially administered Anti-Aß antibodies reduce ß-amyloid deposition by mechanisms both independent of and associated with microglial activation. Journal of Neuroscience 23:3745-3751.

88) Kassed, C.A., T.L. Butler , M.T. Navidomskis , M.N. Gordon , D. Morgan , and K.R. Pennypacker (2003). Mice expressing human mutant presenilin-1 exhibit decreased activation of NF-k B p50 in hippocampal neurons after injury. Molecular Brain Research 110:152-157

89) Chaudhury, A.B., K.M. Gerecke, J.M. Wyss, D.G. Morgan, M.N. Gordon, & S.I. Carroll (2003). Neuregulin-1 and ErbB4 immunoreactivity is associated with neuritic plaques in Alzheimer Disease brain and in a transgenic model of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology 62:42-54.

90) Morgan, D, Jantzen, P. and M. Gordon (2003). Clearance of amyloid by vaccination and nitro-NSAIDs in APP+PS1 transgenic mice. In Alzheimer's Disease and Related Disorders: Research Advances. K. Iqbal and B. Winblad (eds) Ana Aslan Academy of Aging, Bucharest, Romania, pp 525-532.

91) Joseph, J.A., N.A. Denisova, G. Arendash, M. Gordon, D. Diamond, B. Shukitt-Hale and D. Morgan (2003). Blueberry supplementation enhances signaling and prevents behavioral deficits in Alzheimer disease model. Nutritional Neuroscience 6:153-162

92) Dickey, C.A., J.F. Loring, J. Montgomery, M.N. Gordon, P.S. Eastman and D. Morgan (2003) Selectively Reduced Expression of Synaptic Plasticity-Related Genes in APP+PS1 Transgenic Mice. Journal of Neuroscience 23:5219-5226

93) Boyett KW, DiCarlo G, Jantzen PT, Jackson J, O'Leary C, Wilcock D, Morgan D, Gordon MN. (2003). Increased fibrillar beta-amyloid in response to human C1q injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochemical Research 28:83-93.

94) Wilcock, D.M., Munireddy, S.K., Rosenthal, A., Ugen, K.E., Gordon, M.N. and Morgan, D.(2004). Microglial activation facilitates AB plaque removal following intracranial anti-AB antibody administration. Neurobiology of Disease 15:11-20.

95) Dickey,C.A., Gordon,M.N., Mason, J.E., Wilson, N.J., Diamond, D.M., Guzowski, J.M. and Morgan,D. (2004) Amyloid suppresses induction of genes critical for memory

consolidation in APP + PS1 transgenic mice. Journal of Neurochemistry 88:434.

96) Li, Q., C Cao, B Chackerian, J Schiller, M Gordon, KE Ugen and D Morgan (2004). Overcoming antigen masking of anti-Aß antibodies reveals breaking of B cell tolerance in Aß immunized amyloid precursor protein transgenic mice. BMC Neuroscience, 5: 19

97) Morgan, D, and BD Gitter (2004). Evidence supporting a role for anti-Aß antibodies in the treatment of Alzheimer's disease. Neurobiology of Aging, 25:605-608

98) Garcia, M. F., M. N. Gordon, M. Hutton, J. Lewis, E. McGowan, C. A. Dickey, D. Morgan

and G.W. Arendash (2004). The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer’s transgenic mice. Neuroreport 15:73-77

99) Ambegaonkar M,U., Nagle, A.S., Breitner, J.C., Deleon, J., Alamed, J., Wilson, N., Morgan, D., and Gordon, M.N. (2004). The histamine H2-receptor antagonist cimetidine

activates microglia in APP+PS1 transgenic mice. Brain Aging 4:25-40.

100) Wilcock, D., A. Rojiani, A. Rosenthal, J. Alamed, D. Wilson, N. Wilson, M. Freeman, M. Gordon, D. Morgan (2004). Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. Journal of Neuroscience, 24:6144-6151

101) Dickey, C.A, D, Demesquita, D. Morgan and K. Pennypacker (2004). Induction of several

immediate early genes by nerve growth factor in primary neurons and differentiated neuro2A cells. Neurosci Lett. 366: 10-14

102) Herber, D.L., E.G. Severance, J. Cuevas, D. Morgan, and M.N. Gordon (2004). Biochemical and histochemical evidence of nonspecific binding of α7nAChR antibodies to mouse brain tissue. J. Histochem. Cytochem. 52:1367-1376

103) Townsend, K.P. D.R.Shytle, Y. Bai, N. San, J. Zeng, M. Freeman, F.

Fernandez, D. Morgan, P.R. Sanberg and J. Tan (2004). Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J. Neurosci. Res., 78:167-176

104) Gasparini, L., E. Ongini, D. Wilcock, and D Morgan (2004). Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer’s disease. Brain Research Reviews, 48: 400-408.

105) Herber; D.L., L.M. Roth, D. Wilson, N. Wilson; J.E. Mason, D. Morgan and M.N. Gordon (2004). Time-dependent reduction in Aß levels after intracranial LPS administration in APP transgenic mice. Experimental Neurology, 190(1):245-253.

106) Patel, N.V., M.N. Gordon, K. E.. Connor, R.A. Good, R.W. Engelman, J. Mason, D.G. Morgan, T.E. Morgan, C.E. Finch (2005). Caloric Restriction Attenuates Aß-deposition in Alzheimer Disease Models. Neurobiology of Aging, 26:995-1000

107) Ewers M,. M.N. Gordon, D. Morgan and D Woodruff-Pak (2005). Assessing Associative Learning changes of Alzheimer's disease in transgenic APP + PS1 mice: Relation to cortical amyloid pathology. Neurobiol Aging 27:1118-28

108) Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. (2004). Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 1:24.

109) Townsend, KP, T Town, T Mori, L-F Lue, Doug Shytle, P Sanberg, D Morgan, F Fernandez, RA. Flavell and J Tan (2005) CD40 signaling regulates innate and adaptive activation of microglia in response to Aß. Eur J Immunol., 35:901-910

110) Dickey CA, Gordon MN, Wilcock DM, Herber DL, Freeman MJ, Morgan D.(2005) Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC Neurosci. 6:7.

111) Morgan, D (2006) Immunotherapy for Alzheimer's Disease. Journal of Alzheimer's Disease, 9:425-432. 100 years of progress issue

112) Morgan D (2006) Cognitive impairment in transgenic mouse models of amyloid deposition. In Animal Models of Cognitive Impairment, E. Levin and J Buccafusco (eds)., CRC Press, Boca Raton, 183-198.

113) Morgan, D, M Gordon, J. Tan, D. Wilcock and A.M. Rojiani (2005). Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition. Implications for Alzheimer's therapeutics. Journal of Neuropathology and Experimental Neurology 64:743-53.

114) Wecker L. and D. Morgan (2005). Treatment of Parkinson's and Alzheimer's Diseases. In Brody's Human Pharmacology: Molecular to Clinical. Minneman, K, L. Wecker, J. Larner and T.M Brody (eds). Elsevier Mosby Press, Philadelphia, pp 277-284.

115) Morgan, D (2006), Modulation of Microglial Activation State Following Passive Immunization in Amyloid Depositing Transgenic Mice. Neurochemistry International 49: 190-194

116) Morgan, D. (2005). Mechanisms of A-beta Plaque Clearance Following Passive A-beta Immunization. Neurodegenerative Disease, 2:261-266.

117) Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J. (2005). Green tea epigallocatechin-3- gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. Journal of Neuroscience 25:8807-8814.

118) Townsend KP, Shytle DR, Bai Y, San N, Zeng J, Freeman M, Mori T, Fernandez F, Morgan D, Sanberg P, Tan J. (2004). Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J Neurosci. Res.78:167-76.

119) Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN and D Morgan (2006). Intracranial administration of deglycosylated C-terminal- specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of Neuroinflammation 3: 11

120) Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN and, D Morgan (2006) Deglycosylated anti-Aß antibodies reverse cognitive deficits, dramatically reduce parenchymal amyloid with minimal

vascular consequences in aged APP transgenic mice. Journal of Neuroscience 26::5340- 46.

121) Herber DL, Maloney JL, Roth LM, Freeman MJ, Morgan D, Gordon MN. (2006). Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia.53:382-91.

122) Morgan D and Gordon, MN (2007). Immunotherapy for Alzheimer's Disease. in NeuroImmune Pharmacology. Gendelman H and Ikezu T (eds). in press

123) Wilcock DM, Jantzen PT, Li Q, Morgan D and Gordon MN (2007). Aß vaccination, but not nitro-NSAID treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144:950-960

124) Karlnoski R, Wilcock D, Dickey C, Ronan V, Gordon MN, Zhang W, Morgan D* and Taglialatela G (2006) Up-Regulation of Bcl-2 in APP Transgenic Mice is Associated with Neuroprotection. Neurobiology of Disease 25:179-188. * corresponding author

125) Alamed J, Wilcock DM, Diamond DM, Gordon MN and Morgan D (2006). Two-day radial-arm water maze learning and memory task; robust resolution of amyloid related memory deficits in transgenic mice. Nature Protocols 1:1671-1679.

126) Wilcock DM, Gordon MN, Morgan D (2006). Quantification of Cerebral Amyloid Angiopathy and Parenchymal Amyloid Plaques with Congo Red Histochemical Stain. Nature Protocols 1:1591-1595.

127) Li,Q-Y, Gordon MN, Cao C, Ugen KE and Morgan D (2007). Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Aß antibodies. BMC Neuroscience 8:22 (11 pages)

128) Morgan, D (2007). Amyloid, memory and neurogensis. Experimental Neurology, 205:330-5

129) Golub MS, Germann SL, Mercer M, Gordon MN, Morgan DG, Mayer LP, Hoyer PB. Relat (2007). Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. Neurobiology of Aging.

130) Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J, Ehrhart J, Shytle RD, Giunta B, Morgan D, Town T, Tan (2007). Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci U S A. 104:2507-12

131) Dickey,CA, Koren, J, Zhang, Y-J, Xu, Y-F, Jinwal, UK, Birnbaum, MJ, Monks, B, Sun, M, Cheng, JQ, Patterson, C, Bailey, RM, Dunmore, J, Soresh, S, Leon, C, Morgan, D, Petrucelli, L (2008) Akt and CHIP co-regulate tau degradation through coordinated interactions. Proc. Natl. Acad. Sci. 105:3622-7

132) Morgan, D & M.N. Gordon (2008). Amyloid hyperactivity and metabolism. Behavioral Neuroscience. 122:730-2.

133) Li Q, M. Gordon, M.A. Etienne, R P. Hammer & D. Morgan (2008). Contrasting in vivo effects of two peptide-based amyloid β-protein aggregation inhibitors in a transgenic mouse model of amyloid deposition. Cell Transplantation 17:397-408

134) Karlnoski, RA, A Rosenthal, J Alamed, V Ronan, MN Gordon, PE Gottschall,J Grimm, J Pons and D Morgan, (2008). Deglycosylated anti-Aß antibody dose-response effects on pathology and memory in APP transgenic mice. J. Neurimmune Pharmacol. 3:187-97

135) Carty N., K Nash D Lee, M. Mercer PE Gottschall C. Meyers N Muzyczka, MN Gordon and D. Morgan (2008). Adeno-Associated Viral Vector Mediated Gene Delivery of Endothelin Converting Enzyme Reduces Aβ Deposits in APP+PS-1 Transgenic Mice. Molec. Therapy 16:1580-6

136) Obregon D, Hou H, Bai Y, Nikolic WV, Mori T, Luo D, Zeng J, Ehrhart J, Fernandez F, Morgan D, Giunta B, Town T, Tan J. (2008) CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. Neurobiol Dis.29:336-53.

137) Herber DL, Mercer M, Roth LM, Symmonds K, Maloney J, Wilson N, Freeman MJ, Morgan D, Gordon MN.(2007) Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol.;2:222-31

138) Li Q, Gordon M, Etienne MA, Hammer RP, Morgan D. (2008) Contrasting in vivo effects of two peptide-based amyloid-beta protein aggregation inhibitors in a transgenic mouse model of amyloid deposition. Cell Transplant.;17:397-408.

139) Morgan D, Munireddy S, Alamed J, Deleon J, Diamond DM, Bickford P, Hutton M, Lewis J, McGowan E, Gordon MN. (2008). Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice . J Alzheimers Dis. 15:605-14.

140) Dickey C, C Kraft, U Jinwal, J Koren, A Johnson, L Anderson, L Lebson, D Lee, D Dickson, R de Silva, LI Binder, D Morgan, and J Lewis (2009). Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. The American Journal of Pathology,. 174:228-238.

141) Morgan D, Landreth G, Bickford P. (2009) The promise and perils of an Alzheimer disease vaccine: a video debate. J Neuroimmune Pharmacol.;4(1):1-3

142) Karlnoski RA, Rosenthal A, Kobayashi D, Pons J, Alamed J, Mercer M, Li Q, Gordon MN, Gottschall PE, and Morgan D (2009). Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. J. Neuroscience 29:4964-71

143) Lord A, Englund H, Söderberg L, Tucker S, Clausen F, Hillered L, Gordon M, Morgan D, Lannfelt L, Pettersson FE, Nilsson LN. (2009) Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J. 276(4):995-1006.

144) Zhu Y, Obregon D, Hou H, Giunta B, Erhart J, Fernandez F, Mori T, Nikolic W, Zhao Y, Morgan D, Town T, Tan J. (2009) Mutant presenilin-1 deregulated peripheral immunity exacerbates alzheimer-like pathology. J Cell Mol Med. 2009 Nov 9. [Epub ahead of print]

145) Morgan D.(2009The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets. 2009 Mar;8(1):7-15

146) Ajmo JM, Bailey LA, Howell MD, Cortez LK, Pennypacker KR, Mehta HN, Morgan D, Gordon MN, Gottschall PE (2010).  Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice overexpressing APPsw.  J Neurochem 113: 784-795,

1   2   3   4


David g. Morgan, ph. D. 1 Jan 2009 iconContact: Jan Axelson, (608) 512-3729, jan@Lvr com

David g. Morgan, ph. D. 1 Jan 2009 icon[phys 585: Syllabus: Jan 19, 2009]

David g. Morgan, ph. D. 1 Jan 2009 iconНовости рынка розничных финансовых услуг
Совместное предприятие Morgan Stanley и Citigroup станет крупнейшей в США брокерской компанией – Morgan Stanley Smith Barney, управляющей...
David g. Morgan, ph. D. 1 Jan 2009 iconMorgan, M. Patrick. (2003)

David g. Morgan, ph. D. 1 Jan 2009 icon233 cis building 510 Morgan Circle

David g. Morgan, ph. D. 1 Jan 2009 iconThe Morgan Kaufmann Series in Data Management Systems

David g. Morgan, ph. D. 1 Jan 2009 iconBio: Acting Professor of Law, University of California, at Davis (King Hall) (). J. D., Ph. D. (Law and Society), New York University; B. A., Yale University. Thanks to Paul Chevigny, David Garland, Charles Reichmann, David Sklansky and Jerome Skolnick

David g. Morgan, ph. D. 1 Jan 2009 iconJ. D. Gibson et al. "Digital Compression for Multimedia: Principles and Standards," San Francisco, ca: Morgan Kaufmann, 1998."

David g. Morgan, ph. D. 1 Jan 2009 iconLatest references – as of jan 2012

David g. Morgan, ph. D. 1 Jan 2009 iconCurriculum vitae jan-Åke Gustafsson

Разместите кнопку на своём сайте:

База данных защищена авторским правом ©lib.znate.ru 2014
обратиться к администрации
Главная страница